Sanofi S.A., FR0000120578

Jefferies keeps Buy on Sanofi stock at EUR 100 target

Published on 10/08/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales rose 17.80 percent to EUR 11.60 billion. Sanofi stock stood at EUR 71.24 on October 8, 2026 versus EUR 72.03, down 1.10 percent.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 71.24 at Lang & Schwarz on October 8, 2026 at 11:35 a.m. CEST. According to wallstreetONLINE, Jefferies kept its Buy rating and EUR 100.00 price target in an analyst note dated October 6, 2026.

Jefferies sees room for execution

Jefferies analyst Michael Leuchten said Sanofi could modestly exceed expectations with its upcoming quarterly figures and raise its sales outlook, according to wallstreetONLINE. The note also identified strategy updates and acquisitions as important factors for addressing the eventual loss of Dupixent patent protection.

That combination gives the rating a specific test: Sanofi must convert its pipeline and external deals into growth before the flagship medicine faces greater competition. The EUR 100.00 target is therefore tied to execution rather than to the existing Dupixent franchise alone.

Second-quarter growth supplies evidence

Sanofi reported second-quarter 2026 net sales of EUR 11.60 billion, up 17.80 percent from the year-earlier period, according to Scanx. Business earnings per share increased 33.30 percent, while business operating income rose 35.80 percent, showing that operating profit grew faster than sales in that quarter.

The comparison matters because Sanofi is balancing investment in new medicines with pressure from acquisitions and the seasonal vaccine business. The second-quarter figures give Jefferies a recent operating base for its view, while the next report will test whether that pace continued.

October 30 brings the next checkpoint

Sanofi said in an October 6 press release that it will publish third-quarter 2026 results on October 30, 2026. The company also said it is listed on Euronext Paris under SAN and on Nasdaq under SNY, as stated in the same Sanofi release.

At Lang & Schwarz, the stock was down 1.10 percent versus the EUR 72.03 prior close on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.